A Phase 3 interventional study of RiTUXimab Injection in Membranous Nephropathy, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 14 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Centre Hospitalier Universitaire de Nice · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing rituximab in Glomerulonephritis, Membranous — 7 open to participants now, 8 under way, 4 of them phase 3. Rituximab · Glomerulonephritis, Membranous.
Among the 15 studies testing rituximab in Glomerulonephritis, Membranous, this one is the 4th largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 3, and was the 13th registered.
146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.
Browse Glomerulonephritis, Membranous studies →7 of the 15 studies testing rituximab in Glomerulonephritis, Membranous are open now, in 3 countries. Recruiting first, the newest first:
Peking University First Hospital · Sites in China
Ages 18–80
First Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18–75
Beijing Friendship Hospital · Sites in China
Ages 18–70
Peking Union Medical College Hospital · Sites in China
Ages 18–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–90
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 13 (32%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 8 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 46 across 105 interventional studies indexed under Glomerulonephritis, Membranous.
Median enrollment 78 across the 15 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nice is the lead sponsor of 725 studies on the registry; 177 are open to participants now.
Centre Hospitalier Universitaire de Nice has 7 studies filed under Glomerulonephritis, Membranous — fewer than ten, so there is no comparison to draw.
1 of the studies testing rituximab in Glomerulonephritis, Membranous that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029139Shanghai JMT-Bio Inc.A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy | 2027-04-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing rituximab in Glomerulonephritis, Membranous, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Membranous nephropathy is an autoimmune disease affecting the kidney, and the most common cause of nephrotic syndrome in non-diabetic Caucasian adults. The course of this disease is highly variable from one individual to another, ranging from spontaneous remission to progressive chronic kidney disease.
The identification of autoantibodies - e.g., the phospholipase A2 receptor type 1 (PLA2R1) - has promoted the use of immunosuppressive drugs such as rituximab which is now a safe and effective first-line treatment for the management of membranous nephropathy. However, up to 40% of patients do not respond to a first course of rituximab treatment. In nephrotic patients, due to urinary drug loss, rituximab blood level is lower than in other autoimmune diseases treated with rituximab without proteinuria. This high urinary drug loss decreases the drug exposure, potentially explaining why rituximab regimen with low dose infusions (375 mg/m2) did not demonstrate efficacy after month-6 compared to a non-immunosuppressive antiproteinuric treatment in a previous study. In contrast, a regimen of two 1-g infusions two weeks apart was associated with a significantly greater remission rate after 6 months.
Recently, the investigators have shown that after two 1-g rituximab infusions, the rituximab blood level 3 months after the first rituximab infusion, was correlated with the likelihood of remission after 6 and 12 months of the rituximab treatment. Patients with positive rituximab blood level 3 months after treatment had a higher chance of remission at month-6 and at month-12 than patients with an undetectable rituximab level at month-3.
Nowadays, machine learning algorithms are increasingly used in medicine, especially in pharmacology, to predict the exposure to a drug, the initial dose to administer or the interval between two infusions.
The objective of this study is to use a machine learning algorithm predicting the risk of having an undetectable residual level of rituximab 3 months after treatment, in order to propose a personalized treatment management with early additional doses of rituximab for the patients at risk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rituximab treatment 1gram x 2 (day-0, day-15)
Drug: RiTUXimab Injection
personalized treatment based on the algorithm for assessing the risk of having undetectable rituximab level after 3 months: * Patients with a risk between 0 and 50% will receive 1gram x2 (day-0, day-15) * Patients with a risk between 51 and 75% will receive 1gram x 3 (day-0, day-15, day-30) * Patients with a risk between 76 and 100% will receive 1gram x 4 (day-0, day-15, day-30, day-45)
Drug: RiTUXimab Injection
Dose administered will depend on randomisation and for experimental Arm on the risk of having undetectable rituximab level after 3 months
Clinical remission (complete or partial) after 6 months of rituximab initiation
Clinical remission (complete or partial) according to KDIGO and French guidelines: * Complete: urine protein/creatinine ratio (UPCR) \<0.3 g/g and serum albumin\>30 g/L and Glomerular Filtration Rate (estimated by CKD-EPI formula) \>60 ml/min/1.73m2 * Partial: UPCR \<3.5 g/g with a decrease \>50% from baseline (i.e., at first rituximab infusion) and serum albumin improvement or normalization and stable serum creatinine (or increase \<30%).
Time frame: 6 months
Complete clinical remission after 12 months of rituximab initiation
Complete remission: urine protein/creatinine ratio (UPCR) \<0.3 g/g and serum albumin\>30 g/L and Glomerular Filtration Rate (estimated by CKD-EPI formula) \>60 ml/min/1.73m2
Time frame: 12 months
Partial clinical remission after 12 months of rituximab initiation
Partial remission: UPCR \<3.5 g/g with a decrease \>50% from baseline (i.e., at first rituximab infusion) and serum albumin improvement or normalization and stable serum creatinine (or increase \<30%).
Time frame: 12 months
Immunological remission: anti-PLA2R1 depletion
Immunological remission: anti-PLA2R1 depletion (i.e., PLA2R1 titer \< 14 RU/mL by ELISA method) at month-3, month-6 and month-12
Time frame: 12 months
Change in urine protein/creatinine ratio (UPCR)
Percentage of change in urine albumin/creatinine ratio (mg/g) from day-0 to month-3, month-6, month-9, month-12
Time frame: 12 months
Change in serum creatinine
Percentage of change in serum creatinine (μmol/L) from day-0 to month-3, month-6, month-9, month-12
Time frame: 12 months
Change in renal function
Percentage of change in Glomerular Filtration Rate estimated by CKD-EPI formula (mL/min/1.73m²) from day-0 to month-3, month-6, month-9, month-12
Time frame: 12 months
Change in the immunological status of the disease
Percentage of change in anti-PLA2R1 titer (RU/mL) by ELISA (EUROIMMUN Kit) from day-0 to month-3, month-6, month-9, month-12
Time frame: 12 months
Appearance of anti-drug antibodies after rituximab treatment
Serum anti-rituximab antibodies (ng/mL) at month-3, month-6, month-9, month-12
Time frame: 12 months
Rituximab underdosed patients
Percentage of patients with serum rituximab (μg/mL) \>2 μg/mL 3 months after the last infusion
Time frame: 3 months
Serious adverse events
Occurence of Serious adverse events reported
Time frame: 84 months
Adaptation of symptomatic treatment
Number of dose modification of non-immunosuppressive anti-proteinuric treatment during study follow-up
Time frame: 84 months
Model improvement through machine learning
serum creatinine and serum albumin levels, weight, anti-PLA2R1 and rituximab level will be combined to report the risk of having undetectable rituximab level after 3 months (in %) at day-0, day-15, day-30, day-45, month-3, month-6
Time frame: 6 months
Effect of rituximab on immune profiles
Cytokine levels in pg/mL (IFN-γ, IFN-α, IL-12p70, IL-17A, IL-4, IL-5, IL-10, IL-1, IL-6) at day-0 and month-6
Time frame: 6 months
Plan to share: No — not planed
Started Feb 2025 (actual). Primary completion is estimated for Aug 2031, 78 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab
Glomerulonephritis, Membranous →
Centre Hospitalier Universitaire de Nice →